
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Gauging the Risk of Dual Enrollment - Independent Data Integrator - Clinical RSVP Whitepaper






